104 related articles for article (PubMed ID: 24771011)
21. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Vaisman A; Orlov S; Yip J; Hu C; Lim T; Dowar M; Freeman JL; Walfish PG
Head Neck; 2010 Jun; 32(6):689-98. PubMed ID: 20187016
[TBL] [Abstract][Full Text] [Related]
22. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
23. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
24. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study.
Stokkel MP; Verkooijen RB; Bouwsma H; Smit JW
Nucl Med Commun; 2004 Jul; 25(7):683-90. PubMed ID: 15208495
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer.
Szczepanek-Parulska E; Wojewoda-Korbelak M; Borowczyk M; Kaluzna M; Brominska B; Ziemnicka K; Czepczynski R; Baczyk M; Ruchala M
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):115-123. PubMed ID: 30221905
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
Kebebew E; Peng M; Reiff E; Treseler P; Woeber KA; Clark OH; Greenspan FS; Lindsay S; Duh QY; Morita E
Surgery; 2006 Dec; 140(6):960-6; discussion 966-7. PubMed ID: 17188145
[TBL] [Abstract][Full Text] [Related]
27. Circulating Epithelial Cell Characterization and Correlation with Remission and Survival in Patients with Thyroid Cancer.
Lin JD; Liou MJ; Hsu HL; Leong KK; Chen YT; Wang YR; Hung WS; Lee HY; Tsai HJ; Tseng CP
Thyroid; 2018 Nov; 28(11):1479-1489. PubMed ID: 30221579
[TBL] [Abstract][Full Text] [Related]
28. Determining tissue origin of circulating epithelial cells (CEC) in patients with differentiated thyroid cancer by real-time PCR using thyroid mRNA probes.
Sorg S; Pachmann K; Brede-Hekimian K; Freesmeyer M; Winkens T
Cancer Lett; 2015 Jan; 356(2 Pt B):491-5. PubMed ID: 25304372
[TBL] [Abstract][Full Text] [Related]
29. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.
Ma C; Kuang A; Xie J
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD006988. PubMed ID: 19160311
[TBL] [Abstract][Full Text] [Related]
30. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
[TBL] [Abstract][Full Text] [Related]
31. Persistent Elevation of Thyroglobulin in Patient Treated for Differentiated Thyroid Cancer: A Ten-Year Review.
Khan S; Prabhushankar R; Leary E; Khan UZ
Mo Med; 2017; 114(5):387-393. PubMed ID: 30228641
[TBL] [Abstract][Full Text] [Related]
32. [Postoperative treatment of differentiated thyroid carcinoma with radioiodine-131].
Lin YS
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):62-68. PubMed ID: 30704175
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of thyroglobulin in thyroid carcinoma patients after radioiodine therapy.
Jeevanram RK; Shah DH; Kumar BS; Sharma SM; Ganatra RD
Cancer; 1983 Dec; 52(12):2240-4. PubMed ID: 6640494
[TBL] [Abstract][Full Text] [Related]
34. Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap.
Basu S; Dandekar M; Joshi A; D'Cruz A
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1167-71. PubMed ID: 25989850
[No Abstract] [Full Text] [Related]
35. Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer.
Schmidt M; Antke C; Mattes-György K; Hautzel H; Allelein S; Haase M; Dringenberg T; Schott M; Ehlers M
Clin Endocrinol (Oxf); 2021 Jun; 94(6):1004-1011. PubMed ID: 33484159
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.
Clerc J; Verburg FA; Avram AM; Giovanella L; Hindié E; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):918-925. PubMed ID: 28213773
[No Abstract] [Full Text] [Related]
37. Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer.
Sasaki FM; Leal ALG; de Almeida Filho PJ; Mourato FA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):803-804. PubMed ID: 38017326
[No Abstract] [Full Text] [Related]
38. Ferritin concentrations in patients with differentiated thyroid cancer.
Lukinac L; Kalafatić D; Nöthig-Hus D; Lechpammer S; Solter M; Franceschi D; Kusić Z
J Endocrinol Invest; 2000 Jan; 23(1):65-6. PubMed ID: 10698055
[No Abstract] [Full Text] [Related]
39. [Treatment strategy by radioiodine refractory differentiated thyroid cancer].
Mantsopoulos K; Mueller SK; Pavel M; Kuwert T; Meidenbauer N; Fietkau R; Sievert M; Iro H
Laryngorhinootologie; 2022 Apr; 101(4):298-303. PubMed ID: 34583388
[TBL] [Abstract][Full Text] [Related]
40. Increased Numbers of Circulating Tumor Cells in Thyroid Cancer Patients.
Ehlers M; Allelein S; Schwarz F; Hautzel H; Kuebart A; Schmidt M; Haase M; Dringenberg T; Schott M
Horm Metab Res; 2018 Aug; 50(8):602-608. PubMed ID: 30081408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
